Books > Medicine > Pre-clinical medicine: basic sciences > Medical genetics
|
Buy Now
Polyglutamine Disorders (Paperback, Softcover reprint of the original 1st ed. 2018)
Loot Price: R3,655
Discovery Miles 36 550
|
|
Polyglutamine Disorders (Paperback, Softcover reprint of the original 1st ed. 2018)
Series: Advances in Experimental Medicine and Biology, 1049
Expected to ship within 10 - 15 working days
|
This book provides a cutting-edge review of polyglutamine
disorders. It primarily focuses on two main aspects: (1) the
mechanisms underlying the pathologies' development and progression,
and (2) the therapeutic strategies that are currently being
explored to stop or delay disease progression. Polyglutamine
(polyQ) disorders are a group of inherited neurodegenerative
diseases with a fatal outcome that are caused by an abnormal
expansion of a coding trinucleotide repeat (CAG), which is then
translated in an abnormal protein with an elongated glutamine tract
(Q). To date, nine polyQ disorders have been identified and
described: dentatorubral-pallidoluysian atrophy (DRPLA);
Huntington's disease (HD); spinal-bulbar muscular atrophy (SBMA);
and six spinocerebellar ataxias (SCA 1, 2, 3, 6, 7, and 17). The
genetic basis of polyQ disorders is well established and described,
and despite important advances that have opened up the possibility
of generating genetic models of the disease, the mechanisms that
cause neuronal degeneration are still largely unknown and there is
currently no treatment available for these disorders. Further, it
is believed that the different polyQ may share some mechanisms and
pathways contributing to neurodegeneration and disease progression.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.